Last reviewed 2026-04-20 · How we verify

Aveed

At a glance

Approved indications

No approved indications tracked.

Boxed warnings

• WARNING: SERIOUS PULMONARY OIL MICROEMBOLISM (POME) REACTIONS AND ANAPHYLAXIS Serious POME reactions, involving urge to cough, dyspnea, throat tightening, chest pain, dizziness, and syncope; and episodes of anaphylaxis, including life-threatening reactions, have been reported to occur during or immediately after the administration of testosterone undecanoate injection. These reactions can occur after any injection of testosterone undecanoate during the course of therapy, including after the firs

Common side effects

• Acne
• Injection site pain
• Prostatic specific antigen increased
• Estradiol increased
• Hypogonadism
• Fatigue
• Irritability
• Hemoglobin increased
• Insomnia
• Mood swings
• Aggression
• Ejaculation disorder

Serious adverse events

• Prostate cancer
• Deep vein thrombosis
• Pulmonary oil microembolism (POME)
• Anaphylaxis
• Prostatic dysplasia
• Respiratory distress

Key clinical trials

• Body Composition Assessment in Transgender Population.
• Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (PHASE4)
• Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism (PHASE2)
• Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC (PHASE2)
• Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
• Does Human Skeletal Muscle Possess an Epigenetic Memory of Testosterone? (PHASE2, PHASE3)
• Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance (PHASE4)
• Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.